Lumos Pharma, Inc.

LUMO · NASDAQ
Analyze with AI
9/30/2024
6/30/2024
3/31/2024
12/31/2023
Operating Activities
Net Income-$7,467-$7,551-$10,441-$9,457
Dep. & Amort.-$1$2$2$18
Deferred Tax$0$0$0$159
Stock-Based Comp.$379$387$580$524
Change in WC$2,252$782-$3,034$1,552
Other Non-Cash-$169-$131$3,180-$189
Operating Cash Flow-$5,006-$6,380-$12,894-$7,393
Investing Activities
PP&E Inv.$0$0$0-$13,205
Net Acquisitions$0$0$0$7,033
Inv. Purchases$0$0$0-$998
Inv. Sales/Matur.$0$0$1,000$7,170
Other Inv. Act.-$1,000$0$1,000$6,172
Investing Cash Flow$0$0$1,000$6,172
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$11$0$742
Stock Repurch.$16-$11-$5$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$4-$11-$5$17
Financing Cash Flow$1,726$0-$5$742
Forex Effect$0$0$0$8,750
Net Chg. in Cash-$3,280-$6,380-$11,899-$479
Supplemental Information
Beg. Cash$16,799$23,179$35,078$35,557
End Cash$13,519$16,799$23,179$35,078
Free Cash Flow-$5,006-$6,380-$12,894-$20,598